6151964
Last Update Posted: 2025-03-10
Recruiting
All Genders accepted | 18 Years-65 Years |
88 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
A Trial to Learn How Safe AZD9550 is in People With or Without Type 2 Diabetes Who Are Overweight or Obese
AZD9550 is in early development for the treatment of NASH, a type of liver disease that commonly affects overweight and obese participants living with or without T2DM.
The purpose of this study is to investigate the safety, tolerability, and effects of increasing doses of AZD9550 in overweight and obese participants aged 18 through 65 years living with or without T2DM, and to investigate how AZD9550 is absorbed, distributed, and eliminated from the body.
AZD9550 is in early development for the treatment of NASH, a type of liver disease that commonly affects overweight and obese participants living with or without T2DM.
The purpose of this study is to investigate the safety, tolerability, and effects of increasing doses of AZD9550 in overweight and obese participants aged 18 through 65 years living with or without T2DM, and to investigate how AZD9550 is absorbed, distributed, and eliminated from the body.
Eligibility
Relevant conditions:
Non-alcoholic Steatohepatitis (NASH)
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
Data sourced from ClinicalTrials.gov